Bio-Star Closes Physician-Focused Vascular Device Fund
This article was originally published in Start Up
Executive Summary
Vascular-focused Bio-Star, which recently closed on a $26 million private equity fund, includes a distinquished roster of a dozen leading clinicians as investors.
You may also be interested in...
Mach Ventures: Going Small in Device Investing
Many investors worry that they've invested in products not companies: narrow technology plays that limit the size of the exit, or even it's likelihood of happening. But now comes a new venture fund, San Francisco-based Mach Ventures, that is betting that the real opportunity in devices comes precisely from technology plays that are, in fact, more truly products than full-fledged companies.
Bio-Star Fund Taps Clinical Stars
Medical practice changes so rapidly these days that many say if device companies don't have a presence in the operating room every single day, they'll rapidly fall behind the technological curve. The same is true for VCs evaluating the market potential of new technologies, which is why many partners at successful venture firms are physicians. Now, a new VC--Bio-Star Private Equity Fund, founded and funded by practicing physicians-is going a step further.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.